Page last updated: 2024-11-07

sivelestat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sivelestat is a small-molecule inhibitor of the neutrophil elastase (NE) enzyme. It is being studied for its potential to treat acute respiratory distress syndrome (ARDS), a severe lung injury that can occur in patients with COVID-19 and other illnesses. Sivelestat inhibits NE, which is a protease that breaks down proteins in the lungs. Overactive NE can contribute to inflammation and tissue damage in ARDS. Sivelestat has been shown to reduce inflammation and improve lung function in animal models of ARDS. Clinical trials are ongoing to evaluate the efficacy and safety of sivelestat for the treatment of ARDS.'

sivelestat: inhibitor of neutrophil elastase; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107706
CHEMBL ID76688
CHEBI ID135704
SCHEMBL ID123221
MeSH IDM0188942

Synonyms (64)

Synonym
ly544349
CHEMBL76688 ,
ly-544349
D03788
sivelestat (usan/inn)
127373-66-4
331731-18-1
n-(2-(4-(2,2-dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid
elastase inhibitor iv
o-(p-hydroxybenzenesulfonamido)hippuric acid, pivalate (ester)
sivelestat [usan]
sivelestat
ei 546
ly 544349
ono5046
ono-5046
glycine, n-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-
ono-ei-600
CHEBI:135704
2,2-dimethyl-propionic acid 4-[2-(carboxymethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester(ono-5046)
2,2-dimethyl-propionic acid 4-[2-(carboxymethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester
bdbm50084637
2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid
unii-fys6t7f842
2-(2-(4-(pivaloyloxy)phenylsulfonamido)benzamido)acetic acid
sivelestat [usan:inn]
unii-dwi62g0p59
dwi62g0p59 ,
NCGC00346934-01
S8136
gtpl6441
HY-17443
AKOS022176173
SCHEMBL123221
sivelestat [who-dd]
sivelestat [mart.]
sivelestat [mi]
sivelestat [inn]
DTXSID9048304
n-[2-(n'-(carboxymethyl)-aminocarbonyl)-phenyl]-4-t-butylcarbonyloxybenzenesulfonamide
J-005486
bdbm166439
us9073833, sivelestat
2-[(2-{4-[(2,2-dimethylpropanoyl)oxy]benzenesulfonamido}phenyl)formamido]acetic acid
AS-74843
silvelestat
DB12863
Q5646925
elastase inhibitor iv - cas 127373-66-4
ei546
sivelestat (ono-5046)
(2-((4-(pivaloyloxy)phenyl)sulfonamido)benzoyl)glycine ,
ei546;ly544349;ono5046
ono5046;ly544349;ei546
BCP09708
A14184
propanoic acid, 2,2-dimethyl-, 4-[[[2-[[(carboxymethyl)amino]carbonyl]phenyl]amino]sulfonyl]phenyl ester
SDCCGSBI-0633759.P001
NCGC00263570-03
mfcd00889071
CCG-269065
A857463
NCGC00263570-02
abt-d2e7

Research Excerpts

Overview

Sivelestat sodium is an NE inhibitor that can inhibit the inflammatory reaction during systemic inflammatory response syndrome. The drug was developed in Japan in 1991 and is thought to have a prophylactic effect against lung injury after surgery.

ExcerptReferenceRelevance
"The sivelestat is a neutrophil elastase inhibitor thought to have an effect against acute lung injury (ALI) in patients after scheduled cardiac surgery. "( The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass.
Chen, W; Chen, X; Cheng, YQ; Ge, M; Jiang, CY; Jiang, XY; Li, ZS; Lu, LC; Pan, T; Tuoerxun, T; Wang, DJ; Wang, YP; Yang, CJ; Zhang, H; Zhang, HT; Zhou, Q; Zhu, YF, 2023
)
1.75
"Sivelestat sodium is an NE inhibitor that can inhibit the inflammatory reaction during systemic inflammatory response syndrome and alleviate lung injury."( Effects of intravenous sivelestat sodium on prevention of acute respiratory distress syndrome in patients with sepsis: study protocol for a double-blind multicentre randomised controlled trial.
Gao, Z; Li, C; Liu, L; Ma, S; Qiu, H; Xie, J; Yang, Y, 2023
)
1.94
"Sivelestat is a specific neutrophil elastase inhibitor, which has been developed in Japan in 1991."( Protective effects of sivelestat in a caerulein-induced rat acute pancreatitis model.
Cao, J; Liu, Q, 2013
)
1.43
"Sivelestat is a neutrophil elastase inhibitor thought to have a prophylactic effect against lung injury after surgery using bypass."( Sivelestat attenuates lung injury in surgery for congenital heart disease with pulmonary hypertension.
Asano, M; Mishima, A; Nakayama, T; Nomura, N; Saito, T, 2013
)
2.55
"Sivelestat is a small molecular weight neutrophil elastase inhibitor."( [Efficacy of sivelestat for acute lung injury due to severe bacterial pneumonia with systemic inflammatory response syndrome].
Izumikawa, K; Kakeya, H; Kohno, S; Mukae, H; Nakamura, S; Seki, M; Tashiro, T; Yamamoto, Y; Yanagihara, K, 2008
)
1.44
"Sivelestat is a selective neutrophil elastase inhibitor."( Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients.
Gando, S; Hayakawa, M; Hoshino, H; Katabami, K; Sawamura, A; Sugano, M; Wada, T, 2010
)
2.52
"Sivelestat is a specific neutrophil elastase inhibitor, and this study aims to evaluate the effects of sivelestat on postoperative respiratory failure due to AAD."( The effects of a neutrophil elastase inhibitor on the postoperative respiratory failure of acute aortic dissection.
Amano, J; Fukui, D; Furusawa, T; Sakaguchi, M; Seto, T; Terasaki, T; Tsukioka, K; Wada, Y, 2006
)
1.06
"Sivelestat is a selective neutrophil elastase inhibitor used for acute lung injury associated with systemic inflammatory response syndrome."( Beneficial effect of neutrophil elastase inhibitor on anti-Thy1.1 nephritis in rats.
Fujita, T; Kumasaka, R; Murakami, R; Nakamura, N; Okumura, K; Osawa, H; Shimada, M; Yamabe, H, 2008
)
1.07

Effects

Sivelestat has been reported to be effective for ALI associated with systemic inflammatory response syndrome (SIRS) The effectiveness and safety of the drug for infants has not been confirmed.

ExcerptReferenceRelevance
"Sivelestat has been used clinically to treat acute lung injury associated with systemic inflammatory response syndrome."( Neutrophil elastase inhibitor sivelestat attenuates perioperative inflammatory response in pediatric heart surgery with cardiopulmonary bypass.
Inoue, N; Itatani, K; Kitamura, T; Miyaji, K; Oka, N; Shibata, K; Tomoyasu, T, 2013
)
1.4
"Sivelestat has been reported to be effective for ALI associated with systemic inflammatory response syndrome (SIRS), but the effectiveness and safety of the drug for infants has not been confirmed."( Sivelestat treatment for acute respiratory distress syndrome in an infant.
Goto, K; Hagiwara, S; Hidaka, S; Iwasaka, H; Matsumoto, S; Noguchi, T; Shingu, C, 2009
)
2.52

Actions

ExcerptReferenceRelevance
"Sivelestat may inhibit the various inflammatory mediators through NF-kB inhibition."( Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB.
Hagiwara, S; Hasegawa, A; Hidaka, S; Iwasaka, H; Noguchi, T, 2009
)
2.08

Treatment

Sivelestat or edaravone treatment also attenuated the LPS-induced production of pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α) in rat lungs. Sivelest at pretreatment inhibited the activation of nuclear factor (NF) kappaB, caspase 3 and 8 activities.

ExcerptReferenceRelevance
"Sivelestat sodium treatment is not correlated with the reduction of mortality or length of hospital stay, but is associated with reduced serum IL-6 level in patients with COVID-19-associated ARDS."( [Sivelestat sodium for treatment of patients with COVID-19-associated acute respiratory distress syndrome in intensive care unit: a single-center retrospective cohort study].
Hu, H; Liu, Y; Luo, M; Sun, Y; Wu, G; Zeng, Z; Zhao, X, 2023
)
3.26
"Sivelestat treatment significantly reduced the protein level, neutrophil count, neutrophil elastase activity in BALF, and severity of histopathologic findings on day 14 for mice administered with 250 mg/kg of gefitinib."( Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice.
Arimura-Omori, M; Hamada, N; Harada, E; Ikeda-Harada, C; Mikumo, H; Nakanishi, Y; Ogata-Suetsugu, S; Suzuki, K; Yanagihara, T; Yokoyama, T, 2017
)
1.47
"Sivelestat treatment lowered the MDA concentration and the percentage of apoptotic cells bilaterally and ameliorated the testicular histological pattern bilaterally."( Protective effect of sivelestat, a neutrophil elastase inhibitor, on ipsilateral and contralateral testes after unilateral testicular ischaemia-reperfusion injury in rats.
Dimitriadis, F; Kinoshita, Y; Saito, M; Satoh, I; Satoh, K; Shimizu, S; Shomori, K; Tsounapi, P, 2011
)
1.41
"Sivelestat treatment did not improve survival but increased PP and IE lymphocyte numbers significantly and reduced the LP CD8(+) cell percentage and plasma IL-6 concentration compared with controls. "( Neutrophil elastase inhibitor restores gut ischemia reperfusion-induced impairment of gut immunity with reduced plasma interleukin-6 concentrations in mice.
Fukatsu, K; Maeshima, Y; Omata, J; Saitoh, D; Tanabe, K; Yasuhara, H, 2010
)
1.8
"Sivelestat treatment after gut I/R may be useful for maintaining gut immunity and preventing systemic inflammatory responses."( Neutrophil elastase inhibitor restores gut ischemia reperfusion-induced impairment of gut immunity with reduced plasma interleukin-6 concentrations in mice.
Fukatsu, K; Maeshima, Y; Omata, J; Saitoh, D; Tanabe, K; Yasuhara, H, 2010
)
1.8
"Sivelestat or edaravone treatment also attenuated the LPS-induced production of pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α) in rat lungs."( Combined effects of a neutrophil elastase inhibitor (sivelestat sodium) and a free radical scavenger (edaravone) on lipopolysaccharide-induced acute lung injury in rats.
Bao, R; Chen, H; Deng, X; Hou, J; Li, J; Liu, Y; Sun, L; Wang, J; Yang, T; Zhang, J; Zhu, X, 2012
)
1.35
"Sivelestat pretreatment inhibited the activation of nuclear factor (NF) kappaB, caspase 3 and 8 activities, and cytochrome c release."( Neutrophil elastase inhibitor prevents endotoxin-induced liver injury following experimental partial hepatectomy.
Kwon, AH; Qiu, Z, 2007
)
1.06
"Treatment with sivelestat significantly improved the survival rate of the post-CLP septic animals (P = 0.030)."( Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis.
Fukunaga, K; Funakoshi, Y; Hagiwara, T; Hashimoto, S; Ishizaka, A; Kawasako, K; Kitagawa, Y; Maruyama, I; Miyasho, T; Okamoto, M; Saikawa, Y; Suda, K; Suganuma, K; Takeuchi, H; Wada, N; Yamada, S; Yokota, H, 2010
)
0.7
"Treatment with sivelestat significantly improved survival rate, lung permeability and edema, and significantly decreased levels of creatinine, interleukin 6, interleukin 10, and neutrophil elastase activity."( Neutrophil elastase inhibitor improves survival rate after ischemia reperfusion injury caused by supravisceral aortic clamping in rats.
Du, W; Fujimura, N; Itano, O; Kawasako, K; Kitagawa, Y; Kitago, M; Maruyama, I; Matsuda, S; Matsumoto, K; Miyasho, T; Obara, H; Ono, S; Sakamoto, M; Shinoda, M; Suda, K; Takeuchi, H; Tanabe, M; Yagi, H; Yamada, S, 2013
)
0.73
"Treatment with sivelestat significantly improved survival rate with P = 0.032."( Sivelestat improves outcome of crush injury by inhibiting high-mobility group box 1 in rats.
Abe, C; Binh, NH; Cuong, NT; Hara, A; Morita, H; Ogura, S, 2013
)
2.17
"Pretreatment of sivelestat demonstrated a protective effect on both intravascular and extravascular damage in the lung, whereas posttreatment only suppressed the latter damage."( Pretreatment of sivelestat sodium hydrate improves the lung microcirculation and alveolar damage in lipopolysaccharide-induced acute lung inflammation in hamsters.
Fukunaga, M; Iba, T; Kidokoro, A; Sugimotoa, K; Takuhiro, K; Yoshikawa, S, 2006
)
1.01
"Treatment with Sivelestat, a small molecule inhibitor of neutrophil elastase, achieved rapid improvement in oxygenation and chest radiograph findings, and the patient has been in complete remission for 24 months."( Sivelestat relieves respiratory distress refractory to dexamethasone in all-trans retinoic acid syndrome: a report of two cases.
Akaike, H; Kawasaki, K; Miyauchi, A; Ouchi, K, 2006
)
2.12
"Treatment with sivelestat sodium hydrate also decreased serum neutrophil elastase activity."( [Survival by a young woman with malnutrition due to alcoholism and eating disorders and with acute respiratory distress syndrome due to severe pneumonia who showed increased serum neutrophil elastase activity].
Nakajima, H; Nakajima, S; Sawaguchi, H, 2006
)
0.67
"Treatment with sivelestat significantly improved the survival rate. "( Neutrophil elastase inhibitor prevents endotoxin-induced liver injury following experimental partial hepatectomy.
Kwon, AH; Qiu, Z, 2007
)
0.69
"Treatment with sivelestat significantly reduced injury in both the donor and the recipient's native lungs."( Sivelestat reduces reperfusion injury of lungs harvested from endotoxin-primed rats by inhibition of neutrophil-mediated inflammation.
Kondo, T; Niikawa, H; Oishi, H; Sugawara, T; Suzuki, S; Tabata, T, 2007
)
2.12

Toxicity

ExcerptReferenceRelevance
" However, it is considered that these findings could be attributed to the long-term repeated dosing procedure, and were not toxic changes."( [Toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (5). 6-month repeated dose intravenous toxicity study in dogs with 1-month recovery test].
Fujita, T; Ide, M; Ishii, T; Katsumata, T; Numata, H; Okamoto, M; Suzuki, H; Tamura, K, 1998
)
0.3
" No adverse effects on dams were observed in clinical signs, body weight change, food consumption, pregnant, delivery or lactating performances."( [Reproductive and developmental toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (2). Study for effects on pre- and postnatal development in rats, including maternal function
Aze, Y; Chihara, N; Fujita, T; Ikeda, Y; Nakagawa, Y; Nishimura, T; Ozeki, Y; Sakamoto, T; Shinomiya, K; Shirakawa, R; Sugai, S, 1998
)
0.3
" Clinical information including general conditions, mechanical ventilation time, drug cost parameters, and adverse reactions."( Efficacy, safety, and pharmacoeconomics of sivelestat sodium in the treatment of septic acute respiratory distress syndrome: a retrospective cohort study.
Gao, X; Guo, X; Huang, L; Lei, Z; Tian, J; Yang, Y; Zhang, R, 2021
)
0.88
" No adverse events were reported during the study period."( Efficacy, safety, and pharmacoeconomics of sivelestat sodium in the treatment of septic acute respiratory distress syndrome: a retrospective cohort study.
Gao, X; Guo, X; Huang, L; Lei, Z; Tian, J; Yang, Y; Zhang, R, 2021
)
0.88

Compound-Compound Interactions

The patient had acute respiratory distress syndrome due to severe pneumonia. He was treated with pulse methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin.

ExcerptReferenceRelevance
" He was diagnosed as having acute respiratory distress syndrome due to severe pneumonia, and was treated with pulse methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin."( [A case of Legionella pneumonia complicated with acute respiratory distress syndrome treated with methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin].
Arinobu, Y; Himeji, D; Kikuchi, I; Kojima, T; Oguma, A; Ueda, A, 2004
)
0.73
" The authors examined the efficacy of sivelestat in combination with a fluoroquinolone in a Legionella pneumophila pneumonia mouse model."( In vivo efficacy of sivelestat in combination with pazufloxacin against Legionella pneumonia.
Araki, N; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Seki, M; Yamada, K; Yamada, Y; Yamamoto, Y; Yanagihara, K, 2010
)
0.96

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Sivelestat offers a new therapeutic strategy for infantile ARDS/ALI, but further investigation of the indication, administration period, and dosage is required.

ExcerptRelevanceReference
" In the rat perfused liver, the hepatic extraction ratio of ONO-5046 was significantly reduced by adding BSA to the dosing solution."( Hepatic clearance of ONO-5046, a novel neutrophil elastase inhibitor, in rats and in the rat perfused liver.
Higashi, Y; Higashikawa, F; Murakami, T; Okochi, A; Sato, M; Takano, M; Yata, N, 1998
)
0.3
" However, it is considered that these findings could be attributed to the long-term repeated dosing procedure, and were not toxic changes."( [Toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (5). 6-month repeated dose intravenous toxicity study in dogs with 1-month recovery test].
Fujita, T; Ide, M; Ishii, T; Katsumata, T; Numata, H; Okamoto, M; Suzuki, H; Tamura, K, 1998
)
0.3
" Our experience suggests that intravenous sivelestat offers a new therapeutic strategy for infantile ARDS/ALI, but further investigation of the indication, administration period, and dosage is required."( Sivelestat treatment for acute respiratory distress syndrome in an infant.
Goto, K; Hagiwara, S; Hidaka, S; Iwasaka, H; Matsumoto, S; Noguchi, T; Shingu, C, 2009
)
2.06
" Finally, AZD9668 prevented airspace enlargement and small airway wall remodeling in guinea pigs in response to chronic tobacco smoke exposure whether dosed therapeutically or prophylactically."( AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase.
Churg, A; Ekholm, K; Falk-Håkansson, H; Gränse, M; Jungar, C; Kozma, V; Lal, H; Lindahl, M; Ottosson, T; Sanfridson, A; Stevens, T; Wright, JL, 2011
)
0.37
" Our experience suggests that multidrug therapy with Sivelestat offers a new therapeutic strategy for preterm labor, but further investigations of the indications, administration period and dosage are required."( Initial experience using Sivelestat to manage preterm labor with a bulging fetal membrane in pregnant women.
Masaoka, N; Nakajima, Y, 2012
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
N-acylglycineAn N-acyl-amino acid in which amino acid specified is glycine.
pivalate esterA carboxylic ester of pivalic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)142.20000.11007.190310.0000AID1449628
ProthrombinHomo sapiens (human)IC50 (µMol)2.00000.00000.710710.0000AID1058709
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)2.00000.03703.385910.0000AID1058713
Chymotrypsin-like elastase family member 1Sus scrofa (pig)IC50 (µMol)26.09262.18525.171310.0000AID1058705; AID1191735
Trypsin-1Homo sapiens (human)IC50 (µMol)2.00000.00351.532110.0000AID1058707
Trypsin-2Homo sapiens (human)IC50 (µMol)2.00000.00351.58464.4000AID1058707
Neutrophil elastaseHomo sapiens (human)IC50 (µMol)0.12730.00632.073422.3780AID1058710; AID1191721; AID1674570; AID1683148; AID1819015; AID609337; AID66639; AID66643; AID732628
Neutrophil elastaseHomo sapiens (human)Ki0.11530.00201.28669.5499AID1410437; AID1674570; AID1830538; AID66678
Cathepsin GHomo sapiens (human)IC50 (µMol)55.00000.01372.42247.4130AID1058712; AID1191723
Chymotrypsin-like elastase family member 2ASus scrofa (pig)IC50 (µMol)26.09262.18522.34262.5000AID1058705; AID1191735
MyeloblastinHomo sapiens (human)IC50 (µMol)50.17000.34000.34000.3400AID1058711; AID1191722
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Ki0.20000.00000.14803.1800AID66678
Trypsin-3Homo sapiens (human)IC50 (µMol)2.00000.00351.58464.4000AID1058707
Neutrophil elastaseMus musculus (house mouse)IC50 (µMol)0.14540.14540.14540.1454AID1191734
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (126)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
zymogen activationKallikrein-1Homo sapiens (human)
regulation of systemic arterial blood pressureKallikrein-1Homo sapiens (human)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
angiotensin maturationCathepsin GHomo sapiens (human)
monocyte chemotaxisCathepsin GHomo sapiens (human)
protein phosphorylationCathepsin GHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
immune responseCathepsin GHomo sapiens (human)
protein processingCathepsin GHomo sapiens (human)
cytokine-mediated signaling pathwayCathepsin GHomo sapiens (human)
protein metabolic processCathepsin GHomo sapiens (human)
antibacterial humoral responseCathepsin GHomo sapiens (human)
extracellular matrix disassemblyCathepsin GHomo sapiens (human)
platelet activationCathepsin GHomo sapiens (human)
purinergic nucleotide receptor signaling pathwayCathepsin GHomo sapiens (human)
neutrophil activationCathepsin GHomo sapiens (human)
positive regulation of immune responseCathepsin GHomo sapiens (human)
defense response to Gram-negative bacteriumCathepsin GHomo sapiens (human)
defense response to Gram-positive bacteriumCathepsin GHomo sapiens (human)
defense response to fungusCathepsin GHomo sapiens (human)
negative regulation of T cell activationCathepsin GHomo sapiens (human)
neutrophil-mediated killing of gram-positive bacteriumCathepsin GHomo sapiens (human)
cellular response to lipopolysaccharideCathepsin GHomo sapiens (human)
biofilm matrix disassemblyCathepsin GHomo sapiens (human)
positive regulation of platelet aggregationCathepsin GHomo sapiens (human)
proteolysisMyeloblastinHomo sapiens (human)
membrane protein ectodomain proteolysisMyeloblastinHomo sapiens (human)
positive regulation of cell population proliferationMyeloblastinHomo sapiens (human)
antimicrobial humoral responseMyeloblastinHomo sapiens (human)
collagen catabolic processMyeloblastinHomo sapiens (human)
positive regulation of GTPase activityMyeloblastinHomo sapiens (human)
cell-cell junction maintenanceMyeloblastinHomo sapiens (human)
negative regulation of phagocytosisMyeloblastinHomo sapiens (human)
neutrophil extravasationMyeloblastinHomo sapiens (human)
mature conventional dendritic cell differentiationMyeloblastinHomo sapiens (human)
proteolysisTrypsin-3Homo sapiens (human)
digestionTrypsin-3Homo sapiens (human)
antimicrobial humoral responseTrypsin-3Homo sapiens (human)
zymogen activationTrypsin-3Homo sapiens (human)
endothelial cell migrationTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase activityKallikrein-1Homo sapiens (human)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityCathepsin GHomo sapiens (human)
protein bindingCathepsin GHomo sapiens (human)
heparin bindingCathepsin GHomo sapiens (human)
peptidase activityCathepsin GHomo sapiens (human)
serine-type peptidase activityCathepsin GHomo sapiens (human)
receptor ligand activityCathepsin GHomo sapiens (human)
caspase bindingCathepsin GHomo sapiens (human)
serine-type endopeptidase activityMyeloblastinHomo sapiens (human)
signaling receptor bindingMyeloblastinHomo sapiens (human)
protein bindingMyeloblastinHomo sapiens (human)
serine-type peptidase activityMyeloblastinHomo sapiens (human)
enzyme bindingMyeloblastinHomo sapiens (human)
serine-type endopeptidase activityTrypsin-3Homo sapiens (human)
calcium ion bindingTrypsin-3Homo sapiens (human)
protein bindingTrypsin-3Homo sapiens (human)
serine-type peptidase activityTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (39)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
nucleusKallikrein-1Homo sapiens (human)
extracellular exosomeKallikrein-1Homo sapiens (human)
secretory granuleKallikrein-1Homo sapiens (human)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular regionCathepsin GHomo sapiens (human)
extracellular spaceCathepsin GHomo sapiens (human)
nucleusCathepsin GHomo sapiens (human)
lysosomeCathepsin GHomo sapiens (human)
cytosolCathepsin GHomo sapiens (human)
plasma membraneCathepsin GHomo sapiens (human)
cytoplasmic stress granuleCathepsin GHomo sapiens (human)
membraneCathepsin GHomo sapiens (human)
secretory granuleCathepsin GHomo sapiens (human)
azurophil granule lumenCathepsin GHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular exosomeCathepsin GHomo sapiens (human)
cytoplasmCathepsin GHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin GHomo sapiens (human)
plasma membraneMyeloblastinHomo sapiens (human)
collagen-containing extracellular matrixMyeloblastinHomo sapiens (human)
extracellular regionMyeloblastinHomo sapiens (human)
extracellular spaceMyeloblastinHomo sapiens (human)
cytosolMyeloblastinHomo sapiens (human)
plasma membraneMyeloblastinHomo sapiens (human)
azurophil granule lumenMyeloblastinHomo sapiens (human)
intracellular membrane-bounded organelleMyeloblastinHomo sapiens (human)
plasma membrane raftMyeloblastinHomo sapiens (human)
extracellular exosomeMyeloblastinHomo sapiens (human)
extracellular spaceMyeloblastinHomo sapiens (human)
extracellular regionTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
tertiary granule lumenTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (109)

Assay IDTitleYearJournalArticle
AID731570Inhibition of human neutrophil elastase-induced decrease in mICAM1 level expressed in BEAS2B cells assessed as cytoprotective activity after 6 hrs by Western blotting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191733Selectivity index, ratio of IC50 for bovine plasma thrombin to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1058704Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID76714Percent inhibition effect of ONO-5046 on the increase of skin capillary permeability induced by HNE in guinea pigs in vivo on administration of 3 mg/Kg dose iv in guinea pig2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Clarification of mechanism of human sputum elastase inhibition by a new inhibitor, ONO-5046, using electrospray ionization mass spectrometry.
AID1058705Inhibition of pig pancreatic elastase using MeO-Suc-Ala-Ala-Pro-Val-AMC as substrate incubated for 30 mins prior to substrate addition measured for 30 mins by fluorescence assay2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1410437Inhibition of human leukocyte elastase2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
A BODIPY-Tagged Phosphono Peptide as Activity-Based Probe for Human Leukocyte Elastase.
AID1674570Inhibition of human neutrophil elastase2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?
AID1191728Inhibition of bovine plasma thrombin using Benzoyl-Phe-Val-Arg-7-amido-4-methylcoumarin hydrochloride by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID578769Antiproliferative activity against human multidrug-resistant LoVo cells assessed as growth inhibition at 100 ug/ml after 72 hrs2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Simple phosphonic inhibitors of human neutrophil elastase.
AID578654Antiproliferative activity against human LoVo cells assessed as growth inhibition at 100 ug/ml after 72 hrs2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Simple phosphonic inhibitors of human neutrophil elastase.
AID1683148Inhibition of human neutrophil elastase using N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin as substrate measured for every 30 sec for 10 mins by fluorescence based assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Exploration of nitrogen heterocycle scaffolds for the development of potent human neutrophil elastase inhibitors.
AID1819015Inhibition of human neutrophil elastase incubated for 40 mins in presence of Boc-Gln-Ala-Arg-AMC by fluorescence microtiter plate method2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
AID1819025Antiinflammatory activity against bleomycin-induced acute lung injury C57BL/6 mouse model assessed as reduction in pathological changes in lung at 30 mg/kg, ip administered for upto 5 days by HE-staining based assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
AID732627Inhibition of bovine pancreatic chymotrypsin assessed as proteolysis using N-succinyl-Gly-Gly-Phe-p-nitroanilide substrate incubated for 30 mins prior to substrate addition2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID66678Binding affinity against Elastase.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1191732Selectivity index, ratio of IC50 for bovine pancreas chymotrypsin to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1819023Antiinflammatory activity against bleomycin-induced acute lung injury C57BL/6 mouse model assessed as reduction in lung edema by measuring reduction in lung wet/dry ratio at 30 mg/kg, ip administered for upto 5 days relative to control2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
AID1058710Inhibition of human neutrophil elastase using MeO-Suc-Ala-Ala-Pro-Val-AMC as substrate incubated for 30 mins prior to substrate addition measured for 30 mins by fluorescence assay2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1058712Inhibition of human cathepsin G using Suc-Ala-Ala-Pro-Phe-p-nitroanilide as substrate incubated for 30 mins prior to substrate addition measured for 30 mins by spectrophotometry2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1191731Selectivity index, ratio of IC50 for bovine pancreas trypsin to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1058708Inhibition of human kallikrein using H-Pro-Phe-Arg-AMC acetate salt as substrate measured for 30 mins by spectrophotometry2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID76713Percent inhibition effect of ONO-5046 on the increase of skin capillary permeability induced by HNE in guinea pigs in vivo on administration of 10 mg/Kg dose iv in guinea pig2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Clarification of mechanism of human sputum elastase inhibition by a new inhibitor, ONO-5046, using electrospray ionization mass spectrometry.
AID1191742Protection from LPS-induced acute liver injury in C57BL/6 mouse assessed as inhibition of leukocyte infiltration in lung treated 1 hr prior challenge at 100 mg/kg, ip2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1191726Inhibition of bovine pancreatic trypsin using Nalpha-benzoyl-L-arginine-7-amido-4-methylcoumarin2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1058713Inhibition of human urokinase using Z-Gly-Gly-Arg-AMC.HCl as substrate measured for 30 mins by spectrophotometry2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1058709Inhibition of human thrombin using Z-Gly-Gly-Arg-AMC.HCl as substrate measured for 30 mins by spectrophotometry2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID731572Inhibition of human neutrophil elastase-induced desquamation expressed in BEAS2B cells assessed as cytoprotective activity at 100 uM after 12 hrs by trypan blue staining-based bright field microscopic analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191735Inhibition of porcine pancreatic elastase using methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide as substrate preincubated for 15 mins before substrate addition measured after 60 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1819024Antiinflammatory activity against bleomycin-induced acute lung injury C57BL/6 mouse model assessed as fold reduction in lung edema by measuring thickness of the alveolar deterioration at 30 mg/kg, ip administered for upto 5 days by HE-staining relative to2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
AID66639Inhibitory concentration against elastase2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1830538Inhibition of human neutrophil elastase2021Bioorganic & medicinal chemistry letters, 11-15, Volume: 521,5,6,7-Tetrahydro-4H-indazol-4-ones as human neutrophil elastase (HNE) inhibitors.
AID1191744Protection from LPS-induced acute liver injury in C57BL/6 mouse assessed as inhibition of LPS-induced diffuse edematous changes treated 1 hr prior LPS challenge at 100 mg/kg, ip measured 6 hrs post LPS injection by hematoxylin and eosin staining method2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1058699Stability of the compound in phosphate buffer at pH 7.4 at 100 uM by HPLC analysis2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1191730Selectivity index, ratio of IC50 for human cathepsin G to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1191741Protection from LPS-induced acute liver injury in C57BL/6 mouse assessed as inhibition of MPO activity in lung tissue treated 1 hr prior challenge at 100 mg/kg, ip2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1058695Half life in Sprague-Dawley rat liver microsomes by HPLC analysis2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1410427Irreversible inhibition of human leukocyte elastase assessed as ratio of Kinact to Ki using MeO-Suc-Ala-Ala-Pro-Val-pNA as substrate incubated over 60 mins by spectrophotometric method2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
A BODIPY-Tagged Phosphono Peptide as Activity-Based Probe for Human Leukocyte Elastase.
AID609337Inhibition of human neutrophil elastase using N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methyl-coumarin as substrate measured every 30 secs for 10 mins by fluorescence microplate reader2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Design, synthesis and evaluation of N-benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase.
AID578772Antiproliferative activity against human MCF7 cells assessed as growth inhibition at 100 ug/ml after 72 hrs2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Simple phosphonic inhibitors of human neutrophil elastase.
AID731575Inhibition of human neutrophil elastase-induced cell morphological changes expressed in BEAS2B cells assessed as cytoprotective activity at 100 uM incubated 12 to 24 hr by trypan blue staining-based bright field microscopic analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191734Inhibition of recombinant mouse neutrophil elastase using methoxysuccinyl-Ala-Ala-Pro-Val-pnitroanilide as substrate preincubated for 15 mins before substrate addition measured after 90 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1819022Inhibition of elastase (unknown origin)2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
AID1058706Inhibition of human chymotrypsin using Suc-Ala-Ala-Pro-Phe-7-amino-4-methylcoumarin as substrate measured for 30 mins by spectrophotometry2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1819017Inhibition of porcine pancreatic elastase incubated for 40 mins in presence of DQ elastin substrate by fluorescence multiwell plate reader2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
AID732626Inhibition of human pancreatic chymotrypsin assessed as proteolysis using N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide substrate incubated for 30 mins prior to substrate addition2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191729Selectivity index, ratio of IC50 for Pr3 (unknown origin) to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID84880Inhibitory concentration against elastase2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1058696Metabolic stability in human plasma by HPLC analysis2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1191722Inhibition of Pr3 (unknown origin) using t-butyloxycarbonyl-Ala-Ala-Nva-thiobenzyl ester as substrate measured for 180 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID731578Inhibition of human neutrophil elastase-induced antiproliferative activity expressed in BEAS2B cells assessed as cytoprotectivity at 100 uM by MTT assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191746Protection from LPS-induced acute liver injury in C57BL/6 mouse assessed as inhibition of LPS-induced leukocyte infiltration treated 1 hr prior LPS challenge at 100 mg/kg, ip measured 6 hrs post LPS injection by hematoxylin and eosin staining method2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1058703Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID1191724Inhibition of superoxide generation in fMLF/CB-induced human neutrophils preincubated for 5 mins before fMLF/CB treatment by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID578657Antiproliferative activity against human A549 cells after 72 hrs2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Simple phosphonic inhibitors of human neutrophil elastase.
AID731576Inhibition of human neutrophil elastase-induced cell morphological changes expressed in BEAS2B cells assessed as cytoprotective activity after 3 hrs by trypan blue staining-based bright field microscopic analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191740Antiinflammatory activity in C57BL/6 mouse assessed as inhibition of LPS-induced edema compound treated 1 hr prior challenge at 100 mg/kg, ip measured up to 240 mins2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1058711Inhibition of human proteinase 3 using N-MeOSuc-Ala-Ala-Pro-Val-p-nitroanilide as substrate measured for 30 mins by spectrophotometry2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID66643Inhibitory concentration in vitro against Human neutrophil elastase2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Clarification of mechanism of human sputum elastase inhibition by a new inhibitor, ONO-5046, using electrospray ionization mass spectrometry.
AID732629Inhibition of porcine pancreatic elastase assessed as proteolysis using N-succinyl-Ala-Ala-Ala-p-nitroanilide substrate incubated for 15 mins prior to substrate addition measured every 30 seconds2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191747Protection from LPS-induced acute liver injury in C57BL/6 mouse assessed as inhibition of LPS-induced lung tissue destruction treated 1 hr prior LPS challenge at 100 mg/kg, ip measured 6 hrs post LPS injection by hematoxylin and eosin staining method2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID732628Inhibition of human neutrophil elastase assessed as proteolysis using N-(methoxysuccinyl)-Ala-Ala-Pro-Val-p-nitroanilide substrate incubated for 15 mins prior to substrate addition measured every 30 seconds2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191727Inhibition of bovine pancreas chymotrypsin using N-succinyl-Ala-Ala-Pro-Phe-7-amido-4-methylcoumarin by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1708726Protection against KCN-induced necrosis in human PC-12 cells assessed as reduction in KCN-induced cell death at 20 to 100 uM incubated for 5 hrs by LDH release assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both
AID1058707Inhibition of human trypsin using Z-Gly-Gly-Arg-AMC.HCl as substrate measured for 30 mins by spectrophotometry2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.
AID732625Inhibition of human pancreatic chymotrypsin assessed as proteolysis using N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide substrate incubated at 10 uM for 30 mins prior to substrate addition2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1191721Inhibition of human neutrophil elastase measured for 30 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1191745Protection from LPS-induced acute liver injury in C57BL/6 mouse assessed as inhibition of LPS-induced alveolar thickening treated 1 hr prior LPS challenge at 100 mg/kg, ip measured 6 hrs post LPS injection by hematoxylin and eosin staining method2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1410438Inhibition of human leukocyte elastase assessed as association constant2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
A BODIPY-Tagged Phosphono Peptide as Activity-Based Probe for Human Leukocyte Elastase.
AID1191723Inhibition of human cathepsin G using N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide as substrate measured for 180 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID731571Inhibition of human neutrophil elastase-induced increase in sICAM1 level in culture medium expressed in BEAS2B cells assessed as cytoprotective activity after 6 hrs2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
AID1177395Inhibition of FMLP/CB-stimulated elastase release in human neutrophils preincubated for 5 mins before FMLP/CB treatment using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide by spectrophotometry2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Anti-Inflammatory Spirostanol and Furostanol Saponins from Solanum macaonense.
AID1191737Antiinflammatory activity in C57BL/6 mouse assessed as inhibition of human neutrophil elastase-induced edema compound treated 1 hr prior challenge at 100 mg/kg, ip measured up to 240 mins2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1410439Inhibition of human leukocyte elastase assessed as dissociation constant2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
A BODIPY-Tagged Phosphono Peptide as Activity-Based Probe for Human Leukocyte Elastase.
AID1191725Inhibition of elastase release in fMLF/CB-induced human neutrophils preincubated for 5 mins before fMLF/CB treatment using methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide as substrate by spectrophotometry2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1819026Antiinflammatory activity against bleomycin-induced acute lung injury C57BL/6 mouse model assessed as reduction in inflammatory cell infiltration in lung at 30 mg/kg, ip administered for upto 5 days by HE-staining based assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1345798Human elastase, neutrophil expressed (S1: Chymotrypsin)2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Design, synthesis and evaluation of N-benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (343)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's67 (19.53)18.2507
2000's113 (32.94)29.6817
2010's125 (36.44)24.3611
2020's38 (11.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.64 (24.57)
Research Supply Index5.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index49.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (8.22%)5.53%
Reviews16 (4.53%)6.00%
Case Studies24 (6.80%)4.05%
Observational1 (0.28%)0.25%
Other283 (80.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sivelestat for the Treatment of Adult Patients With Acute Respiratory Distress Syndrome Due to COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial [NCT05697016]238 participants (Anticipated)Interventional2023-01-31Not yet recruiting
A Pilot Study of Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy [NCT01170845]31 participants (Actual)Interventional2007-03-31Completed
A Randomized Controlled Study of Sivelestat Sodium in Improving Pulmonary Insufficiency After Aortic Dissection Arch Surgery Under Hypothermic Circulatory Arrest [NCT05343338]168 participants (Anticipated)Interventional2022-04-20Not yet recruiting
Efficacy of Sivelestat Sodium in the Treatment of ARDS With SIRS, a Multicenter Double-blind Randomized Controlled Clinical Trial [NCT04909697]Phase 4324 participants (Anticipated)Interventional2022-04-18Recruiting
Effect of Early Treatment With Sivelestat Sodium on Lung Function and Inflammatory Response of ARDS Patients [NCT05020210]560 participants (Anticipated)Observational2021-09-30Enrolling by invitation
A Pilot Study of Perioperative Application of Sivelestat Sodium in Acute Type A Aortic Dissection Patients With Preoperative Moderate to Severe Hypoxemia to Shorten the Duration of Postoperative Invasive Mechanical Ventilation [NCT05874700]30 participants (Anticipated)Interventional2023-05-31Not yet recruiting
Efficacy and Safety of Sivelestat Sodium Hydrate in Acute Lung Injury Associated With Systemic Inflammatory Response Syndrome, Compared With the Conventional Treatment in Japan [NCT00219375]Phase 4649 participants (Actual)Interventional2004-06-30Completed
Clinical Study of Neutrophil Elastase Inhibitor in Treatment of Acute Respiratory Distress Syndrome Patients With Mechanical Ventilation Caused by Sepsis [NCT05672472]100 participants (Anticipated)Interventional2023-01-10Not yet recruiting
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury [NCT00036062]Phase 1/Phase 2600 participants Interventional2001-08-31Completed
ONO-5046Na Phase II Study - A Pilot Study for Patients With Acute Respiratory Failure [NCT00417326]Phase 2174 participants (Actual)Interventional2006-12-31Completed
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis: Multicenter, Random, Double-blind, Parallel, Placebo Control Clinical Trials [NCT04973670]Phase 3238 participants (Anticipated)Interventional2021-10-11Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]